
Boston Scientific Invests $1.5B in MiRus, Option to Acquire TAVR System
Boston Scientific Corporation announced a strategic investment of $1.5 billion in MiRus LLC, a privately held company developing biomaterials and solutions for cardiovascular and orthopedic diseases. This investment grants Boston Scientific a 33.75% non-voting common equity interest in MiRus and an exclusive option to acquire MiRus's TAVR-Structural Heart NewCo subsidiary, which holds assets related to the SIEGEL transcatheter aortic valve replacement (TAVR) system, for an additional $3.0 billion upon achievement of clinical and regulatory milestones. The SIEGEL TAVR system is a novel, nickel-free, balloon-expandable valve made with a proprietary rhenium alloy, currently undergoing the STAR pivotal clinical trial.
Key Highlights
- Boston Scientific invested $1.5 billion in MiRus LLC for a 33.75% non-voting equity stake.
- The agreement includes an exclusive option to acquire MiRus's TAVR business for an additional $3.0 billion.
- The SIEGEL TAVR system is a novel, nickel-free, balloon-expandable valve made with a proprietary rhenium alloy.
- The SIEGEL valve can be delivered through an 8 French expandable sheath, approximately 50% smaller than current options.
- MiRus has initiated the STAR pivotal trial for the SIEGEL TAVR system in up to 1,025 patients.
- The investment is expected to be immaterial to Boston Scientific's adjusted earnings per share in 2026.
- Boston Scientific also has an option to acquire mitral and tricuspid replacement valve assets from MiRus.
Price Impact
More from BSX